Please login to the form below

Not currently logged in

IL-13 inhibitor

This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly expands dermatology portfolio with $1.1bn Dermira deal

Lilly expands dermatology portfolio with $1.1bn Dermira deal

The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Dermira gained the bulk of the rights to the IL-13 inhibitor in a

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....